{"status": "OK", "response": {"docs": [{"type_of_material": "News", "blog": [], "news_desk": "Business", "lead_paragraph": "Congress wants a second look at how private firms profit from public research after Pfizer and the National Institutes of Health developed a potentially lucrative new drug.", "headline": {"seo": "Questions for Public-Private Pact That Led to Xeljanz", "main": "Seeking Profit for Taxpayers in Potential of New Drug", "print_headline": "Seeking Profit For Taxpayers In Potential Of New Drug"}, "abstract": "Congress wants another look at how private firms profit from public research after Pfizer and National Institutes of Health developed potentially lucrative new arthritis drug; federal research and development spending, already down 10 percent since 2010, faces additional 8 percent cut, or $54 billion, through 2017.", "print_page": "1", "word_count": "1123", "_id": "5147b36afdc5926e77000c32", "snippet": "Congress wants a second look at how private firms profit from public research after Pfizer and the National Institutes of Health developed a potentially lucrative new drug.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2013/03/19/business/questions-for-public-private-pact-that-led-to-xeljanz.html", "multimedia": [{"subtype": "wide", "url": "images/2013/03/19/business/Pharma3/Pharma3-thumbWide.jpg", "height": 126, "width": 190, "legacy": {"wide": "images/2013/03/19/business/Pharma3/Pharma3-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "type": "image"}, {"subtype": "xlarge", "url": "images/2013/03/19/business/Pharma1/Pharma1-articleLarge.jpg", "height": 608, "width": 600, "legacy": {"xlargewidth": "600", "xlarge": "images/2013/03/19/business/Pharma1/Pharma1-articleLarge.jpg", "xlargeheight": "608"}, "type": "image"}, {"subtype": "thumbnail", "url": "images/2013/03/19/business/Pharma3/Pharma3-thumbStandard.jpg", "height": 75, "width": 75, "legacy": {"thumbnailheight": "75", "thumbnail": "images/2013/03/19/business/Pharma3/Pharma3-thumbStandard.jpg", "thumbnailwidth": "75"}, "type": "image"}], "subsection_name": null, "keywords": [{"value": "Drugs (Pharmaceuticals)", "is_major": "Y", "rank": "1", "name": "subject"}, {"value": "National Institutes of Health", "is_major": "Y", "rank": "2", "name": "organizations"}, {"value": "Pfizer Inc", "is_major": "Y", "rank": "3", "name": "organizations"}, {"value": "O'Shea, John J", "is_major": "N", "rank": "4", "name": "persons"}, {"value": "Federal Budget (US)", "is_major": "Y", "rank": "5", "name": "subject"}, {"value": "Research", "is_major": "Y", "rank": "6", "name": "subject"}, {"value": "Wyden, Ron", "is_major": "N", "rank": "7", "name": "persons"}, {"value": "Arthritis", "is_major": "Y", "rank": "8", "name": "subject"}], "byline": {"contributor": "", "person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Jonathan", "lastname": "WEISMAN"}], "original": "By JONATHAN WEISMAN"}, "document_type": "article", "pub_date": "2013-03-19T00:00:00Z", "section_name": "Business Day"}, {"type_of_material": "News", "blog": [], "news_desk": "Business", "lead_paragraph": "The 1 percent drop in drug spending was partly a sign of the rising use of generics, but experts warn that the high cost of specialty medicines could reverse the downturn.", "headline": {"seo": "Use of Generics Produces an Unusual Drop in Drug Spending", "main": "U.S. Drug Costs Dropped in 2012, but Rises Loom", "print_headline": "U.S. Drug Costs Dropped in 2012, But Rises Loom"}, "abstract": "One percent drop in prescription drug spending in 2012 was partly a sign of the rising use of generics, but experts warn that the high cost of specialty medicines could reverse the downturn; potential for higher spending on drugs comes as nation is struggling over how to contain health care costs, which many experts agree is major threat to country's fiscal condition.", "print_page": "1", "word_count": "1288", "_id": "5147afcdfdc5926e77000c28", "snippet": "The 1 percent drop in drug spending was partly a sign of the rising use of generics, but experts warn that the high cost of specialty medicines could reverse the downturn.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2013/03/19/business/use-of-generics-produces-an-unusual-drop-in-drug-spending.html", "multimedia": [{"subtype": "wide", "url": "images/2013/03/19/business/Drug/Drug-thumbWide.jpg", "height": 126, "width": 190, "legacy": {"wide": "images/2013/03/19/business/Drug/Drug-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "type": "image"}, {"subtype": "xlarge", "url": "images/2013/03/19/business/Drug/Drug-articleLarge.jpg", "height": 400, "width": 600, "legacy": {"xlargewidth": "600", "xlarge": "images/2013/03/19/business/Drug/Drug-articleLarge.jpg", "xlargeheight": "400"}, "type": "image"}, {"subtype": "thumbnail", "url": "images/2013/03/19/business/Drug/Drug-thumbStandard.jpg", "height": 75, "width": 75, "legacy": {"thumbnailheight": "75", "thumbnail": "images/2013/03/19/business/Drug/Drug-thumbStandard.jpg", "thumbnailwidth": "75"}, "type": "image"}], "subsection_name": null, "keywords": [{"value": "Drugs (Pharmaceuticals)", "is_major": "Y", "rank": "1", "name": "subject"}, {"value": "Health Insurance and Managed Care", "is_major": "N", "rank": "2", "name": "subject"}, {"value": "Prices (Fares, Fees and Rates)", "is_major": "N", "rank": "3", "name": "subject"}, {"value": "IMS Health", "is_major": "N", "rank": "4", "name": "organizations"}, {"value": "Generic Brands and Products", "is_major": "N", "rank": "5", "name": "subject"}, {"value": "Medicine and Health", "is_major": "Y", "rank": "6", "name": "subject"}], "byline": {"contributor": "", "person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Katie", "lastname": "THOMAS"}], "original": "By KATIE THOMAS"}, "document_type": "article", "pub_date": "2013-03-19T00:00:00Z", "section_name": "Business Day"}, {"type_of_material": "News", "blog": [], "news_desk": "Science", "lead_paragraph": "With the Human Brain Project, Henry Markram and his team in Lausanne, Switzerland, are trying to bring together scientists worldwide to create a \u201cvirtual copy of the human brain.\u201d", "headline": {"seo": "Bringing a Virtual Brain to Life", "main": "Bringing a Virtual Brain to Life", "print_headline": "Bringing a Virtual Brain to Life"}, "abstract": "Dr Henry Markram has set out to simulate entire human brain on supercomputer with Human Brain Project, sprawling and controversial initiative involving more than 150 institutions around world; project was awarded 10-year grant of up to $1.3 billion in January, but some scientists have expressed serious reservations about its viability.", "print_page": "1", "word_count": "1515", "_id": "5147837dfdc5926e77000ba4", "snippet": "With the Human Brain Project, Henry Markram and his team in Lausanne, Switzerland, are trying to bring together scientists worldwide to create a \u201cvirtual copy of the human brain.\u201d", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2013/03/19/science/bringing-a-virtual-brain-to-life.html", "multimedia": [{"subtype": "wide", "url": "images/2013/03/19/science/19BRAI1/19BRAI-thumbWide.jpg", "height": 126, "width": 190, "legacy": {"wide": "images/2013/03/19/science/19BRAI1/19BRAI-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "type": "image"}, {"subtype": "xlarge", "url": "images/2013/03/19/science/19BRAI1/19BRAI-articleLarge.jpg", "height": 895, "width": 600, "legacy": {"xlargewidth": "600", "xlarge": "images/2013/03/19/science/19BRAI1/19BRAI-articleLarge.jpg", "xlargeheight": "895"}, "type": "image"}, {"subtype": "thumbnail", "url": "images/2013/03/19/science/19BRAI1/19BRAI-thumbStandard.jpg", "height": 75, "width": 75, "legacy": {"thumbnailheight": "75", "thumbnail": "images/2013/03/19/science/19BRAI1/19BRAI-thumbStandard.jpg", "thumbnailwidth": "75"}, "type": "image"}], "subsection_name": null, "keywords": [{"value": "Brain", "is_major": "Y", "rank": "1", "name": "subject"}, {"value": "Markram, Henry (1962- )", "is_major": "Y", "rank": "2", "name": "persons"}, {"value": "Swiss Federal Institute of Technology", "is_major": "N", "rank": "3", "name": "organizations"}, {"value": "Supercomputers", "is_major": "Y", "rank": "4", "name": "subject"}, {"value": "Research", "is_major": "N", "rank": "5", "name": "subject"}, {"value": "Computers and the Internet", "is_major": "N", "rank": "6", "name": "subject"}], "byline": {"contributor": "", "person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Tim", "lastname": "REQUARTH"}], "original": "By TIM REQUARTH"}, "document_type": "article", "pub_date": "2013-03-19T00:00:00Z", "section_name": "Science"}, {"type_of_material": "News", "blog": [], "news_desk": "Business", "lead_paragraph": "Prime Minister Shinzo Abe portrayed the proposed pact with the United States and other nations as Japan\u2019s \u201clast chance\u201d to remain an economic power in Asia.", "headline": {"seo": "Japan Seeks to Join Pacific Trade Pact", "main": "Japan Seeks to Join Pacific Trade Negotiations", "print_headline": "Japan Seeks to Join Pacific Trade Negotiations"}, "abstract": null, "print_page": "", "word_count": "1353", "_id": "51470c02fdc5926e7700001c", "snippet": "Prime Minister Shinzo Abe portrayed the proposed pact with the United States and other nations as Japan\u2019s \u201clast chance\u201d to remain an economic power in Asia.", "source": "International Herald Tribune", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2013/03/16/business/global/japan-seeks-to-join-pacific-trade-pact.html", "multimedia": [{"width": 190, "url": "images/2013/03/16/business/global/16trade/16trade-thumbWide.jpg", "height": 126, "subtype": "wide", "legacy": {"wide": "images/2013/03/16/business/global/16trade/16trade-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "type": "image"}, {"width": 600, "url": "images/2013/03/16/business/global/16trade/16trade-articleLarge.jpg", "height": 417, "subtype": "xlarge", "legacy": {"xlargewidth": "600", "xlarge": "images/2013/03/16/business/global/16trade/16trade-articleLarge.jpg", "xlargeheight": "417"}, "type": "image"}], "subsection_name": null, "keywords": [{"rank": "1", "is_major": "N", "value": "International Trade and World Market", "name": "subject"}, {"rank": "3", "is_major": "N", "value": "Abe, Shinzo", "name": "persons"}, {"rank": "2", "is_major": "N", "value": "Japan", "name": "glocations"}, {"rank": "4", "is_major": "N", "value": "Far East, South and Southeast Asia and Pacific Areas", "name": "glocations"}], "byline": {"contributor": "", "person": [{"organization": "", "role": "reported", "firstname": "Hiroko", "rank": 1, "lastname": "TABUCHI"}], "original": "By HIROKO TABUCHI"}, "document_type": "article", "pub_date": "2013-03-16T00:00:00Z", "section_name": "Business Day"}], "meta": {"hits": 4, "offset": 0, "time": 508}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}